Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Long-Term Debt Repayments (2021 - 2025)

Oncology Institute (TOI) has disclosed Long-Term Debt Repayments for 2 consecutive years, with $20.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Long-Term Debt Repayments changed N/A year-over-year to $20.0 million, compared with a TTM value of $20.0 million through Sep 2025, changed N/A, and an annual FY2021 reading of $7.2 million, up 2469.04% over the prior year.
  • Long-Term Debt Repayments was $20.0 million for Q1 2025 at Oncology Institute, up from $5.1 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $20.0 million in Q1 2025 and bottomed at $94000.0 in Q1 2021.